Measles immunity and immunization in developing countries of Africa: a review

Abdurrahman, M.B.; Taqi, A.M.

African Journal of Medicine and Medical Sciences 10(1-2): 57-62

1981


ISSN/ISBN: 0309-3913
PMID: 6287828
Document Number: 180952
Although an effective vaccine against measles has been available for several years, the disease is still prevelant in Africa. The disease is characterized by its occurrence in younger age groups and high morbidity and mortality. The African child is born with a high transplacentally acquired measles antibody level. However, the antibody declines rapidly, so that it is virtually absent after the age of 6 months. The measles vaccine with which the African child is immunized is of reduced potency because of poor storage and transportation facilities and the adverse effect of tropical climate on the vaccine. The pattern of measles immunity in Africa is different from that in developed countries. Measles immunization schedule in Africa, as in any other part of the world, must be based on sound epidemiological and serological data.

Document emailed within 1 workday
Secure & encrypted payments